Back |
home / stock / eols / eols message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: EOLS 21% v6,3M c4.46 f33,7M preMH5.6 H5.09 S4.18 | znewcar1 | investorshangout | 12/17/2020 10:50:57 PM |
whytestocks: $EOLS must see | whytestocks | investorshangout | 05/26/2020 4:25:45 PM |
whytestocks: $EOLS News Article - Evolus Expands Board of Directors with Appointment of Independent | whytestocks | investorshangout | 07/15/2019 3:55:40 PM |
whytestocks: $EOLS News Article - Evolus Accelerates Next Phase of U.S. Launch of Jeuveau(TM) with ' | whytestocks | investorshangout | 06/05/2019 2:45:41 PM |
whytestocks: $EOLS News Article - Evolus Announces Publication of U.S. Phase III Pivotal Trial Resul | whytestocks | investorshangout | 03/21/2019 6:45:40 PM |
znewcar1: 20.16% 4,837,213 28.91 27,274,991 Still going! | znewcar1 | investorshangout | 02/07/2019 9:50:32 PM |
znewcar1: 26.00% v6,892,778 c25.83 f27,274,991 News big recent vol. is impressive FDA approval. | znewcar1 | investorshangout | 02/05/2019 9:31:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management ...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective J...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™...